|
1
|
Jänne PA, Baik C, Su WC, Johnson ML,
Hayashi H, Nishio M, Kim DW, Koczywas M, Gold KA, Steuer CE, et al:
Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR
inhibitor-resistant, EGFR-Mutated Non-small cell lung cancer.
Cancer Discov. 12:74–89. 2022. View Article : Google Scholar
|
|
2
|
Jordan EJ, Kim HR, Arcila ME, Barron D,
Chakravarty D, Gao J, Chang MT, Ni A, Kundra R, Jonsson P, et al:
Prospective comprehensive molecular characterization of lung
adenocarcinomas for efficient patient matching to approved and
emerging therapies. Cancer Discov. 7:596–609. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xu K, Wang H, Li S, Zhao L, Liu X, Liu Y,
Ye L, Liu X, Li L and He Y: Changing profile of lung cancer
clinical characteristics in China: Over 8-year population-based
study. Chin Med J Pulm Crit Care Med. 1:188–194. 2023. View Article : Google Scholar
|
|
4
|
Passaro A, Jänne PA, Mok T and Peters S:
Overcoming therapy resistance in EGFR-mutant lung cancer. Nat
Cancer. 2:377–391. 2021. View Article : Google Scholar
|
|
5
|
Westover D, Zugazagoitia J, Cho BC, Lovly
CM and Paz-Ares L: Mechanisms of acquired resistance to first- and
second-generation EGFR tyrosine kinase inhibitors. Ann Oncol.
29(suppl 1): i10–i19. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tian X, Gu T, Lee MH and Dong Z: Challenge
and countermeasures for EGFR targeted therapy in non-small cell
lung cancer. Biochim Biophys Acta Rev Cancer. 1877:1886452022.
View Article : Google Scholar
|
|
7
|
Rotow J and Bivona TG: Understanding and
targeting resistance mechanisms in NSCLC. Nat Rev Cancer.
17:637–658. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Han J, Wang Y, Zhong L, Zhou H, Yu M, Li
Y, Lu Y, Wang Y and Zhu J: T790M mutation in stage Iv EGFR-mutated
NSCLC patient with acquired resistance reverted to original 19Del
mutation after administration of a series of precision treatments:
a case report. Precis Clin Med. 1:129–133. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sun SY: Taking early preventive
interventions to manage the challenging issue of acquired
resistance to third-generation EGFR inhibitors. Chin Med J Pulm
Crit Care Med. 1:3–10. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu J, Zhang Y, Liu K, Shi J, Yan M, Xu J,
Liu Y and Zhang S: Cross-talk between cancer-associated fibroblasts
and dormant cancer cells: Current status and promising therapeutic
potential. Cancer Cell Int. 26:242025. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rahal Z, El Darzi R, Moghaddam SJ, Cascone
T and Kadara H: Tumour and microenvironment crosstalk in NSCLC
progression and response to therapy. Nat Rev Clin Oncol.
22:463–482. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Spranger S and Gajewski TF: Impact of
oncogenic pathways on evasion of antitumour immune responses. Nat
Rev Cancer. 18:139–147. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
de visser KE and Joyce JA: The evolving
tumor microenvironment: From cancer initiation to metastatic
outgrowth. Cancer Cell. 41:374–403. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hou J, Karin M and Sun B: Targeting
cancer-promoting inflammation-have anti-inflammatory therapies come
of age? Nat Rev Clin Oncol. 18:261–279. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fisher DT, Appenheimer MM and Evans SS:
The two faces of IL-6 in the tumor microenvironment. Semin Immunol.
26:38–47. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Abulaiti A, Shintani Y, Funaki S, Nakagiri
T, Inoue M, Sawabata N, Minami M and Okumura M: Interaction between
non-small-cell lung cancer cells and fibroblasts via enhancement of
TGF-β signaling by IL-6. Lung Cancer. 82:204–213. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Song Z, Lin Y, Ye X, Feng C, Lu Y, Yang G
and Dong C: Expression of IL-1α and IL-6 is associated with
progression and prognosis of human cervical cancer. Med Sci Monit.
22:4475–4481. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ma Y, Ren Y, Dai ZJ, Wu CJ, Ji YH and Xu
J: IL-6, IL-8 and TNF-alpha levels correlate with disease stage in
breast cancer patients. Adv Clin Exp Med. 26:421–426. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Feng L, Qi Q, Wang P, Chen H, Chen Z, Meng
Z and Liu L: Serum levels of IL-6, IL-8, and IL-10 are indicators
of prognosis in pancreatic cancer. J Int Med Res. 46:5228–5236.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liang B, Li L, Miao R, Wang J, Chen Y, Li
Z, Zou X and Zhou M: Expression of interleukin-6 and integrin ανβ6
in colon cancer: Association with clinical outcomes and prognostic
implications. Cancer Invest. 37:174–184. 2019. View Article : Google Scholar
|
|
21
|
Tsai MS, Chen WC, Lu CH and Chen MF: The
prognosis of head and neck squamous cell carcinoma related to
immunosuppressive tumor microenvironment regulated by IL-6
signaling. Oral Oncol. 91:47–55. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kaur S, Bansal Y, Kumar R and Bansal G: A
panoramic review of IL-6: Structure, pathophysiological roles and
inhibitors. Bioorg Med Chem. 28:1153272020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rose-John S, Jenkins BJ, Garbers C, Moll
JM and Scheller J: Targeting IL-6 trans-signalling: Past, present
and future prospects. Nat Rev Immunol. 23:666–681. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yao X, Huang J, Zhong H, Shen N, Faggioni
R, Fung M and Yao Y: Targeting interleukin-6 in inflammatory
autoimmune diseases and cancers. Pharmacol Ther. 141:125–139. 2014.
View Article : Google Scholar
|
|
25
|
Nozawa H, Chiu C and Hanahan D:
Infiltrating neutrophils mediate the initial angiogenic switch in a
mouse model of multi-stage carcinogenesis. Proc Natl Acad Sci USA.
1032006.
|
|
26
|
Walter M, Liang S, Ghosh S, Hornsby PJ and
Li R: Interleukin 6 secreted from adipose stromal cells promotes
migration and invasion of breast cancer cells. Oncogene.
28:2745–2755. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nagasaki T, Hara M, Nakanishi H, Takahashi
H, Sato M and Takeyama H: Interleukin-6 released by colon
cancer-associated fibroblasts is critical for tumour angiogenesis:
Anti-interleukin-6 receptor antibody suppressed angiogenesis and
inhibited tumour-stroma interaction. Br J Cancer. 110:469–478.
2014. View Article : Google Scholar
|
|
28
|
Kumari N, Dwarakanath BS, Das A and Bhatt
AN: Role of interleukin-6 in cancer progression and therapeutic
resistance. Tumour Biol. 37:11553–11572. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wolf J, Waetzig GH, Chalaris A, Reinheimer
TM, Wege H, Rose-John S and Garbers C: Different soluble forms of
the interleukin-6 family signal transducer gp130 fine-tune the
blockade of interleukin-6 trans-signaling. J Biol Chem.
291:16186–16196. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Scheller J, Chalaris A, Schmidt-Arras D
and Rose-John S: The pro- and anti-inflammatory properties of the
cytokine interleukin-6. Biochim Biophys Acta. 1813:878–888. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Orange ST, Leslie J, Ross M, Mann DA and
Wackerhage H: The exercise IL-6 enigma in cancer. Trends Endocrinol
Metab. 34:749–763. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Arnold P, Lückstädt W, Li W, Boll I, Lokau
J, Garbers C, Lucius R, Rose-John S and Becker-Pauly C: Joint
reconstituted signaling of the IL-6 receptor via extracellular
vesicles. Cells. 9:13072020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Heink S, Yogev N, Garbers C, Herwerth M,
Aly L, Gasperi C, Husterer V, Croxford AL, Möller-Hackbarth K,
Bartsch HS, et al: Trans-presentation of IL-6 by dendritic cells is
required for the priming of pathogenic TH17 cells. Nat Immunol.
18:74–85. 2017. View Article : Google Scholar :
|
|
34
|
Schaper F and Rose-John S: Interleukin-6:
Biology, signaling and strategies of blockade. Cytokine Growth
Factor Rev. 26:475–487. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hu X, Li J, Fu M, Zhao X and Wang W: The
JAK/STAT signaling pathway: From bench to clinic. Signal Transduct
Target Ther. 6:4022021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen RY, Yen CJ, Liu YW, Guo CG, Weng CY,
Lai CH, Wang JM, Lin YJ and Hung LY: CPAP promotes angiogenesis and
metastasis by enhancing STAT3 activity. Cell Death Differ.
27:1259–1273. 2020. View Article : Google Scholar :
|
|
37
|
Chen H, Zhou W, Bian A, Zhang Q, Miao Y,
Yin X, Ye J, Xu S, Ti C, Sun Z, et al: Selectively targeting STAT3
using a small molecule inhibitor is a potential therapeutic
strategy for pancreatic cancer. Clin Cancer Res. 29:815–830. 2023.
View Article : Google Scholar
|
|
38
|
McGuire JJ, Frieling JS, Lo CH, Li T,
Muhammad A, Lawrence HR, Lawrence NJ, Cook LM and Lynch CC:
Mesenchymal stem cell-derived interleukin-28 drives the selection
of apoptosis resistant bone metastatic prostate cancer. Nat Commun.
12:7232021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hong C, Schubert M, Tijhuis AE, Requesens
M, Roorda M, van den Brink A, Ruiz LA, Bakker PL, van der Sluis T,
Pieters W, et al: cGAS-STING drives the IL-6-dependent survival of
chromosomally instable cancers. Nature. 607:366–373. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wong GL, Manore SG, Doheny DL and Lo HW:
STAT family of transcription factors in breast cancer: Pathogenesis
and therapeutic opportunities and challenges. Semin Cancer Biol.
86(Pt 3): 84–106. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Huynh J, Chand A, Gough D and Ernst M:
Therapeutically exploiting STAT3 activity in cancer-using tissue
repair as a road map. Nat Rev Cancer. 19:82–96. 2019. View Article : Google Scholar
|
|
42
|
Wang R, Du TT, Liu WQ, Liu YC, Yang YD, Hu
JP, Ji M, Yang BB, Li L and Chen XG: Discovery, optimization, and
evaluation of novel N-(Benzimidazol-5-yl)-1,3,4-thiadiazol-2-amine
analogues as potent STAT3 inhibitors for cancer treatment. J Med
Chem. 66:12373–12395. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tamura T, Kato Y, Ohashi K, Ninomiya K,
Makimoto G, Gotoda H, Kubo T, Ichihara E, Tanaka T, Ichimura K, et
al: Potential influence of interleukin-6 on the therapeutic effect
of gefitinib in patients with advanced non-small cell lung cancer
harbouring EGFR mutations. Biochem Biophys Res Commun. 495:360–367.
2018. View Article : Google Scholar
|
|
44
|
Li L, Li Z, Lu C, Li J, Zhang K, Lin C,
Tang X, Liu Z, Zhang Y, Han R, et al: Ibrutinib reverses
IL-6-induced osimertinib resistance through inhibition of Laminin
α5/FAK signaling. Commun Biol. 5:1552022. View Article : Google Scholar
|
|
45
|
Hsu HS, Lin JH, Hsu TW, Su K, Wang CW,
Yang KY, Chiou SH and Hung SC: Mesenchymal stem cells enhance lung
cancer initiation through activation of IL-6/JAK2/STAT3 pathway.
Lung Cancer. 75:167–177. 2012. View Article : Google Scholar
|
|
46
|
Xie C, Liang C, Wang R, Yi K, Zhou X, Li
X, Chen Y, Miao D, Zhong C and Zhu J: Resveratrol suppresses lung
cancer by targeting cancer stem-like cells and regulating tumor
microenvironment. J Nutr Biochem. 112:1092112023. View Article : Google Scholar
|
|
47
|
Thuya WL, Cao Y, Ho PC, Wong AL, Wang L,
Zhou J, Nicot C and Goh BC: Insights into IL-6/JAK/STAT3 signaling
in the tumor microenvironment: Implications for cancer therapy.
Cytokine Growth Factor Rev. 85:26–42. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Soler MF, Abaurrea A, Azcoaga P, Araujo AM
and Caffarel MM: New perspectives in cancer immunotherapy:
Targeting IL-6 cytokine family. J Immunother Cancer.
11:e0075302023. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chen SF, Zhang ZY and Zhang JL: Matrine
increases the inhibitory effects of afatinib on H1975 cells via the
IL-6/JAK1/STAT3 signaling pathway. Mol Med Rep. 16:2733–2739. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yuquan B, Hexiao T, Laiyi W, Gaofeng P,
Xuefeng Z, Ming X, Yanhong W, Li Z and Jinping Z: Interaction
between epidermal growth factor receptor and interleukin-6 receptor
in NSCLC progression. J Cell Biochem. 120:872–881. 2019. View Article : Google Scholar
|
|
51
|
Wang J, Wang Y, Zheng C, Hou K, Zhang T,
Qu X, Liu Y, Kang J, Hu X and Che X: Tyrosine kinase
inhibitor-induced IL-6/STAT3 activation decreases sensitivity of
EGFR-mutant non-small cell lung cancer to icotinib. Cell Biol Int.
42:1292–1299. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Liu C, Yang L, Xu H, Zheng S, Wang Z, Wang
S, Yang Y, Zhang S, Feng X, Sun N, et al: Systematic analysis of
IL-6 as a predictive biomarker and desensitizer of immunotherapy
responses in patients with non-small cell lung cancer. BMC Med.
20:1872022. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Looyenga BD, Hutchings D, Cherni I,
Kingsley C, Weiss GJ and Mackeigan JP: STAT3 is activated by JAK2
independent of key oncogenic driver mutations in non-small cell
lung carcinoma. PLoS One. 7:e308202012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Pine SR, Mechanic LE, Enewold L,
Chaturvedi AK, Katki HA, Zheng YL, Bowman ED, Engels EA, Caporaso
NE and Harris CC: Increased levels of circulating interleukin 6,
interleukin 8, C-reactive protein, and risk of lung cancer. J Natl
Cancer Inst. 103:1112–1122. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Silva EM, Mariano VS, Pastrez PRA, Pinto
MC, Castro AG, Syrjanen KJ and Longatto-Filho A: High systemic IL-6
is associated with worse prognosis in patients with non-small cell
lung cancer. PLoS One. 12:e01811252017. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Jones SA and Jenkins BJ: Recent insights
into targeting the IL-6 cytokine family in inflammatory diseases
and cancer. Nat Rev Immunol. 18:773–789. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Islas-vazquez L, Prado-Garcia H,
Aguilar-Cazares D, Meneses-Flores M, Galicia-velasco M,
Romero-Garcia S, Camacho-Mendoza C and Lopez-Gonzalez JS: LAP
TGF-Beta Subset of CD4(+)CD25(+)CD127(-) Treg cells is increased
and overexpresses LAP TGF-Beta in lung adenocarcinoma patients.
Biomed Res Int. 2015:4309432015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Brooks GD, McLeod L, Alhayyani S, Miller
A, Russell PA, Ferlin W, Rose-John S, Ruwanpura S and Jenkins BJ:
IL6 Trans-signaling promotes KRAS-driven lung carcinogenesis.
Cancer Res. 76:866–876. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Ujiie H, Tomida M, Akiyama H, Nakajima Y,
Okada D, Yoshino N, Takiguchi Y and Tanzawa H: Serum hepatocyte
growth factor and interleukin-6 are effective prognostic markers
for non-small cell lung cancer. Anticancer Res. 32:3251–3258.
2012.PubMed/NCBI
|
|
60
|
Liao C, Yu Z, Guo W, Liu Q, Wu Y, Li Y and
Bai L: Prognostic value of circulating inflammatory factors in
non-small cell lung cancer: A systematic review and meta-analysis.
Cancer Biomark. 14:469–481. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Sheng J, Fang W, Liu X, Xing S, Zhan J, Ma
Y, Huang Y, Zhou N, Zhao H and Zhang L: Impact of gefitinib in
early stage treatment on circulating cytokines and lymphocytes for
patients with advanced non-small cell lung cancer. Onco Targets
Ther. 10:1101–1110. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Jia Y, Li X, Zhao C, Jiang T, Zhao S,
Zhang L, Liu X, Shi J, Qiao M, Luo J, et al: Impact of serum
vascular endothelial growth factor and interleukin-6 on treatment
response to epidermal growth factor receptor tyrosine kinase
inhibitors in patients with non-small-cell lung cancer. Lung
Cancer. 125:22–28. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Komi DEA and Redegeld FA: Role of mast
cells in shaping the tumor microenvironment. Clin Rev Allergy
Immunol. 58:313–325. 2020. View Article : Google Scholar :
|
|
64
|
Nilsson MB, Sun H, Diao L, Tong P, Liu D,
Li L, Fan Y, Poteete A, Lim SO, Howells K, et al: Stress hormones
promote EGFR inhibitor resistance in NSCLC: Implications for
combinations with β-blockers. Sci Transl Med. 9:eaao43072017.
View Article : Google Scholar
|
|
65
|
Jia Y, Li X, Zhao C, Jiang T, Zhao S,
Zhang L, Liu X, Shi J, Qiao M, Luo J, et al: Impact of serum
vascular endothelial growth factor and interleukin-6 on treatment
response to epidermal growth factor receptor tyrosine kinase
inhibitors in patients with non-small-cell lung cancer. Lung
Cancer. 125:22–28. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Oh YT, Chen Z, Wang D, Ramalingam SS and
Sun SY: Induction of IL6/STAT3-dependent TRAIL expression that
contributes to the therapeutic efficacy of osimertinib in EGFR
mutant NSCLC cells. Oncogene. 44:2315–2327. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Kim SM, Kwon OJ, Hong YK, Kim JH, Solca F,
Ha SJ, Soo RA, Christensen JG, Lee JH and Cho BC: Activation of
IL-6R/JAK1/STAT3 signaling induces de novo resistance to
irreversible EGFR inhibitors in non-small cell lung cancer with
T790M resistance mutation. Mol Cancer Ther. 11:2254–2264. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Yao Z, Fenoglio S, Gao DC, Camiolo M,
Stiles B, Lindsted T, Schlederer M, Johns C, Altorki N, Mittal V,
et al: TGF-beta IL-6 axis mediates selective and adaptive
mechanisms of resistance to molecular targeted therapy in lung
cancer. Proc Natl Acad Sci USA. 107:15535–15540. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Liang Q, Gong M, Zou JH, Luo MY, Jiang LL,
Wang C, Shen NX, Zhang MC, Xu L, Lei HM, et al: A phosphoglycerate
mutase 1 allosteric inhibitor overcomes drug resistance to
EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling
pathway in lung adenocarcinoma. Drug Resist Updat. 68:1009572023.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ and
Settleman J: Drug resistance via feedback activation of Stat3 in
oncogene-addicted cancer cells. Cancer Cell. 26:207–221. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Li L, Han R, Xiao H, Lin C, Wang Y, Liu H,
Li K, Chen H, Sun F, Yang Z, et al: Metformin sensitizes
EGFR-TKI-resistant human lung cancer cells in vitro and in vivo
through inhibition of IL-6 signaling and EMT reversal. Clin Cancer
Res. 20:2714–2726. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Zheng X, Lu G, Yao Y and Gu W: An
Autocrine IL-6/IGF-1R loop mediates EMT and promotes tumor growth
in non-small cell lung cancer. Int J Biol Sci. 15:1882–1891. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Shi Q, Godschalk RWL and van Schooten FJ:
Inflammation and the chemical carcinogen benzo[a]pyrene: Partners
in crime. Mutat Res Rev Mutat Res. 774:12–24. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Klammer H, Mladenov E, Li F and Iliakis G:
Bystander effects as manifestation of intercellular communication
of DNA damage and of the cellular oxidative status. Cancer Lett.
356:58–71. 2015. View Article : Google Scholar
|
|
75
|
Maynard A, McCoach CE, Rotow JK, Harris L,
Haderk F, Kerr DL, Yu EA, Schenk EL, Tan W, Zee A, et al:
Therapy-induced evolution of human lung cancer revealed by
single-cell RNA sequencing. Cell. 182:1232–1251.e22. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Isomoto K, Haratani K, Hayashi H, Shimizu
S, Tomida S, Niwa T, Yokoyama T, Fukuda Y, Chiba Y, Kato R, et al:
Impact of EGFR-TKI treatment on the tumor immune microenvironment
in EGFR mutation-positive non-small cell lung cancer. Clin Cancer
Res. 26:2037–2046. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Tsukamoto H, Nishikata R, Senju S and
Nishimura Y: Myeloid-derived suppressor cells attenuate TH1
development through IL-6 production to promote tumor progression.
Cancer Immunol Res. 1:64–76. 2013. View Article : Google Scholar
|
|
78
|
Tsukamoto H, Fujieda K, Senju S, Ikeda T,
Oshiumi H and Nishimura Y: Immune-suppressive effects of
interleukin-6 on T-cell-mediated anti-tumor immunity. Cancer Sci.
109:523–530. 2018. View Article : Google Scholar :
|
|
79
|
Ohno Y, Kitamura H, Takahashi N, Ohtake J,
Kaneumi S, Sumida K, Homma S, Kawamura H, Minagawa N, Shibasaki S
and Taketomi A: IL-6 down-regulates HLA class II expression and
IL-12 production of human dendritic cells to impair activation of
antigen-specific CD4(+) T cells. Cancer Immunol Immunother.
65:193–204. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Huseni MA, Wang L, Klementowicz JE, Yuen
K, Breart B, Orr C, Liu LF, Li Y, Gupta V, Li C, et al: CD8+ T
cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1
immunotherapy. Cell Rep Med. 4:1008782023. View Article : Google Scholar
|
|
81
|
Patel SA, Nilsson MB, Yang Y, Le X, Tran
HT, Elamin YY, Yu X, Zhang F, Poteete A, Ren X, et al: IL6 mediates
suppression of T- and NK-cell function in EMT-associated
TKI-resistant EGFR-mutant NSCLC. Clin Cancer Res. 29:1292–1304.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Kuo IY, Yang YE, Yang PS, Tsai YJ, Tzeng
HT, Cheng HC, Kuo WT, Su WC, Chang CP and Wang YC: Converged
Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an
immunosuppressive lung tumor microenvironment. Theranostics.
11:7029–7044. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Zhang N, Zeng Y, Du W, Zhu J, Shen D, Liu
Z and Huang JA: The EGFR pathway is involved in the regulation of
PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in
EGFR-mutated non-small cell lung cancer. Int J Oncol. 49:1360–1368.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Kang M, Park C, Kim SH, Yoon SW, Suh KJ,
Kim YJ, Ock CY, Kim M, Keam B, Kim TM, et al: Programmed
death-ligand 1 expression level as a predictor of EGFR tyrosine
kinase inhibitor efficacy in lung adenocarcinoma. Transl Lung
Cancer Res. 10:699–711. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Li J, Xu J, Yan X, Jin K, Li W and Zhang
R: Targeting interleukin-6 (IL-6) sensitizes Anti-PD-L1 treatment
in a colorectal cancer preclinical model. Med Sci Monit.
24:5501–5508. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Fan K, Yang C, Fan Z, Huang Q, Zhang Y,
Cheng H, Jin K, Lu Y, Wang Z, Luo G, et al: MUC16 C
terminal-induced secretion of tumor-derived IL-6 contributes to
tumor-associated treg enrichment in pancreatic cancer. Cancer Lett.
418:167–175. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Hu G, Cheng P, Pan J, Wang S, Ding Q,
Jiang Z, Cheng L, Shao X, Huang L and Huang J: An IL6-adenosine
positive feedback loop between CD73+ γδTregs and CAFs promotes
tumor progression in human breast cancer. Cancer Immunol Res.
8:1273–1286. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Salazar Y, Zheng X, Brunn D, Raifer H,
Picard F, Zhang Y, Winter H, Guenther S, Weigert A, Weigmann B, et
al: Microenvironmental Th9 and Th17 lymphocytes induce metastatic
spreading in lung cancer. J Clin Invest. 130:3560–3575. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Kim HY, Jhun JY, Cho ML, Choi JY, Byun JK,
Kim EK, Yoon SK, Bae SH, Chung BH and Yang CW: Interleukin-6
upregulates Th17 response via mTOR/STAT3 pathway in
acute-on-chronic hepatitis B liver failure. J Gastroenterol.
49:1264–1273. 2014. View Article : Google Scholar
|
|
90
|
Zheng Y, Sun L, Jiang T, Zhang D, He D and
Nie H: TNFα promotes Th17 cell differentiation through IL-6 and
IL-1β produced by monocytes in rheumatoid arthritis. J Immunol Res.
2014:3853522014. View Article : Google Scholar
|
|
91
|
Tsukamoto H, Fujieda K, Hirayama M, Ikeda
T, Yuno A, Matsumura K, Fukuma D, Araki K, Mizuta H, Nakayama H, et
al: Soluble IL6R expressed by myeloid cells reduces tumor-specific
Th1 differentiation and drives tumor progression. Cancer Res.
77:2279–2291. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Wu J, Gao FX, Wang C, Qin M, Han F, Xu T,
Hu Z, Long Y, He XM, Deng X, et al: IL-6 and IL-8 secreted by
tumour cells impair the function of NK cells via the STAT3 pathway
in oesophageal squamous cell carcinoma. J Exp Clin Cancer Res.
38:3212019. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Gotthardt D, Putz EM, Straka E, Kudweis P,
Biaggio M, Poli V, Strobl B, Müller M and Sexl V: Loss of STAT3 in
murine NK cells enhances NK cell-dependent tumor surveillance.
Blood. 124:2370–2379. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Kalluri R and Zeisberg M: Fibroblasts in
cancer. Nat Rev Cancer. 6:392–401. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Karagiannis GS, Poutahidis T, Erdman SE,
Kirsch R, Riddell RH and Diamandis EP: Cancer-associated
fibroblasts drive the progression of metastasis through both
paracrine and mechanical pressure on cancer tissue. Mol Cancer Res.
10:1403–1418. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Meador CB and Hata AN: Acquired resistance
to targeted therapies in NSCLC: Updates and evolving insights.
Pharmacol Ther. 210:1075222020. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Mikubo M, Inoue Y, Liu G and Tsao MS:
Mechanism of drug tolerant persister cancer cells: The landscape
and clinical implication for therapy. J Thorac Oncol. 16:1798–1809.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Bullock E, Rozyczko A, Shabbir S, Tsoupi
I, Young AIJ, Travnickova J, Gómez-Cuadrado L, Mabruk Z, Carrasco
G, Morrow E, et al: Cancer-associated fibroblast driven paracrine
IL-6/STAT3 signaling promotes migration and dissemination in
invasive lobular carcinoma. Breast Cancer Res. 27:1212025.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Tan J, Zhu L, Shi J, Zhang J, Kuang J, Guo
Q, Zhu X, Chen Y, Zhou C and Gao X: Evaluation of drug resistance
for EGFR-TKIs in lung cancer via multicellular lung-on-a-chip. Eur
J Pharm Sci. 199:1068052024. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Ishiguro Y, Ishiguro H and Miyamoto H:
Epidermal growth factor receptor tyrosine kinase inhibition
up-regulates interleukin-6 in cancer cells and induces subsequent
development of interstitial pneumonia. Oncotarget. 4:550–559. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Ochi K, Suzawa K, Thu YM, Takatsu F,
Tsudaka S, Zhu Y, Nakata K, Takeda T, Shien K, Yamamoto H, et al:
Drug repositioning of tranilast to sensitize a cancer therapy by
targeting cancer-associated fibroblast. Cancer Sci. 113:3428–3436.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Shien K, Papadimitrakopoulou vA, Ruder D,
Behrens C, Shen L, Kalhor N, Song J, Lee JJ, Wang J, Tang X, et al:
JAK1/STAT3 activation through a proinflammatory cytokine pathway
leads to resistance to molecularly targeted therapy in non-small
cell lung cancer. Mol Cancer Ther. 16:2234–2245. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Mantovani A, Marchesi F, Malesci A, Laghi
L and Allavena P: Tumour-associated macrophages as treatment
targets in oncology. Nat Rev Clin Oncol. 14:399–416. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Xiang X, Wang J, Lu D and Xu X: Targeting
tumor-associated macrophages to synergize tumor immunotherapy.
Signal Transduct Target Ther. 6:752021. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Zhang B, Zhang Y, Zhao J, Wang Z, Wu T, Ou
W, Wang J, Yang B, Zhao Y, Rao Z and Gao J: M2-polarized
macrophages contribute to the decreased sensitivity of EGFR-TKIs
treatment in patients with advanced lung adenocarcinoma. Med Oncol.
31:1272014. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Zhou J, Qu Z, Sun F, Han L, Li L, Yan S,
Stabile LP, Chen LF, Siegfried JM and Xiao G: Myeloid STAT3
promotes lung tumorigenesis by transforming tumor
immunosurveillance into tumor-promoting inflammation. Cancer
Immunol Res. 5:257–268. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Hu Z, Sui Q, Jin X, Shan G, Huang Y, Yi Y,
Zeng D, Zhao M, Zhan C, Wang Q, et al: IL6-STAT3-C/EBPβ-IL6
positive feedback loop in tumor-associated macrophages promotes the
EMT and metastasis of lung adenocarcinoma. J Exp Clin Cancer Res.
43:632024. View Article : Google Scholar
|
|
108
|
Lin G, Lin L, Chen X, Chen L, Yang J, Chen
Y, Qian D, Zeng Y and Xu Y: PPAR-γ/NF-kB/AQP3 axis in M2 macrophage
orchestrates lung adenocarcinoma progression by upregulating IL-6.
Cell Death Dis. 15:5322024. View Article : Google Scholar
|
|
109
|
Chen S, Lu K, Hou Y, You Z, Shu C, Wei X,
Wu T, Shi N, Zhang G, Wu J, et al: YY1 complex in M2 macrophage
promotes prostate cancer progression by upregulating IL-6. J
Immunother Cancer. 11:e0060202023. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Che D, Zhang S, Jing Z, Shang L, Jin S,
Liu F, Shen J, Li Y, Hu J, Meng Q and Yu Y: Macrophages induce EMT
to promote invasion of lung cancer cells through the IL-6-mediated
COX-2/PGE2/β-catenin signalling pathway. Mol Immunol. 90:197–210.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Wu Y, Yi M, Niu M, Mei Q and Wu K:
Myeloid-derived suppressor cells: An emerging target for anticancer
immunotherapy. Mol Cancer. 21:1842022. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Tang J, Liu X, Gong Y, Zhu J, Huang M,
Ding Z, Yu M, Tie Y, Li Q and Wang Y: Epidermal growth factor
receptor tyrosine kinase inhibitors (EGFR-TKIs) impact on immune
microenvironment in non-small cell lung cancer (NSCLC). J Clin
Oncol. 36(15_Suppl): e211542018. View Article : Google Scholar
|
|
113
|
Yang Z, Guo J, Weng L, Tang W, Jin S and
Ma W: Myeloid-derived suppressor cells-new and exciting players in
lung cancer. J Hematol Oncol. 13:102020. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
vasquez-Dunddel D, Pan F, Zeng Q,
Gorbounov M, Albesiano E, Fu J, Blosser RL, Tam AJ, Bruno T, Zhang
H, et al: STAT3 regulates arginase-I in myeloid-derived suppressor
cells from cancer patients. J Clin Invest. 123:1580–1589. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Altorki NK, Markowitz GJ, Gao D, Port JL,
Saxena A, Stiles B, McGraw T and Mittal V: The lung
microenvironment: An important regulator of tumour growth and
metastasis. Nat Rev Cancer. 19:9–31. 2019. View Article : Google Scholar :
|
|
116
|
Neo SY, Tong L, Chong J, Liu Y, Jing X,
Oliveira MMS, Chen Y, Chen Z, Lee K, Burduli N, et al:
Tumor-associated NK cells drive MDSC-mediated tumor immune
tolerance through the IL-6/STAT3 axis. Sci Transl Med.
16:eadi29522024. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Gabrilovich DI and Nagaraj S:
Myeloid-derived suppressor cells as regulators of the immune
system. Nat Rev Immunol. 9:162–174. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Condamine T and Gabrilovich DI: Molecular
mechanisms regulating myeloid-derived suppressor cell
differentiation and function. Trends Immunol. 32:19–25. 2011.
View Article : Google Scholar
|
|
119
|
Weber R, Groth C, Lasser S, Arkhypov I,
Petrova V, Altevogt P, Utikal J and Umansky V: IL-6 as a major
regulator of MDSC activity and possible target for cancer
immunotherapy. Cell Immunol. 359:1042542021. View Article : Google Scholar
|
|
120
|
Jeong H, Koh J, Kim S, Yim J, Song SG, Kim
H, Li Y, Lee SH, Chung YK, Kim H, et al: Cell-intrinsic PD-L1
signaling drives immunosuppression by myeloid-derived suppressor
cells through IL-6/jak/Stat3 in PD-L1-high lung cancer. J
Immunother Cancer. 13:e0106122025. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Weber R, Riester Z, Hüser L, Sticht C,
Siebenmorgen A, Groth C, Hu X, Altevogt P, Utikal JS and Umansky V:
IL-6 regulates CCR5 expression and immunosuppressive capacity of
MDSC in murine melanoma. J Immunother Cancer. 8:e0009492020.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Song L, Rawal B, Nemeth JA and Haura EB:
JAK1 activates STAT3 activity in non-small-cell lung cancer cells
and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling.
Mol Cancer Ther. 10:481–494. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Yang Y, Wang W, Chang H, Han Z, Yu X and
Zhang T: Reciprocal regulation of miR-206 and IL-6/STAT3 pathway
mediates IL6-induced gefitinib resistance in EGFR-mutant lung
cancer cells. J Cell Mol Med. 23:7331–7341. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Murakami T, Takigawa N, Ninomiya T, Ochi
N, Yasugi M, Honda Y, Kubo T, Ichihara E, Hotta K, Tanimoto M and
Kiura K: Effect of AZD1480 in an epidermal growth factor
receptor-driven lung cancer model. Lung Cancer. 83:30–36. 2014.
View Article : Google Scholar
|
|
125
|
Padda SK, Reckamp KL, Koczywas M, Neal JW,
Kawashima J, Kong S, Huang DB, Kowalski M and Wakelee HA: A phase
1b study of erlotinib and momelotinib for the treatment of
EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small
cell lung cancer. Cancer Chemother Pharmacol. 89:105–115. 2022.
View Article : Google Scholar :
|
|
126
|
Hong D, Kurzrock R, Kim Y, Woessner R,
Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, et al:
AZD9150, a next-generation antisense oligonucleotide inhibitor of
STAT3 with early evidence of clinical activity in lymphoma and lung
cancer. Sci Transl Med. 7:314ra1852015. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Nan J, Du Y, Chen X, Bai Q, Wang Y, Zhang
X, Zhu N, Zhang J, Hou J, Wang Q and Yang J: TPCA-1 is a direct
dual inhibitor of STAT3 and NF-κB and regresses mutant
EGFR-Associated human non-small cell lung cancers. Mol Cancer Ther.
13:617–629. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Chiu HC, Chou DL, Huang CT, Lin WH, Lien
TW, Yen KJ and Hsu JT: Suppression of Stat3 activity sensitizes
gefitinib-resistant non small cell lung cancer cells. Biochem
Pharmacol. 81:1263–1270. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Hedvat M, Huszar D, Herrmann A, Gozgit JM,
Schroeder A, Sheehy A, Buettner R, Proia D, Kowolik CM, Xin H, et
al: The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and
oncogenesis in solid tumors. Cancer Cell. 16:487–497. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Xin H, Herrmann A, Reckamp K, Zhang W, Pal
S, Hedvat M, Zhang C, Liang W, Scuto A, Weng S, et al:
Antiangiogenic and antimetastatic activity of JAK inhibitor
AZD1480. Cancer Res. 71:6601–6610. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Li R, Huang Y and Lin J: Distinct effects
of general anesthetics on lung metastasis mediated by
IL-6/JAK/STAT3 pathway in mouse models. Nat Commun. 11:6422020.
View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Cao W, Liu Y, Zhang R, Zhang B, Wang T,
Zhu X, Mei L, Chen H, Zhang H, Ming P and Huang L:
Homoharringtonine induces apoptosis and inhibits STAT3 via
IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer
cells. Sci Rep. 5:84772015. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Lou W, Chen Y, Zhu KY, Deng H, Wu T and
Wang J: Polyphyllin I overcomes EMT-associated resistance to
erlotinib in lung cancer cells via IL-6/STAT3 pathway inhibition.
Biol Pharm Bull. 40:1306–1313. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Shi Y, Gao W, Lytle NK, Huang P, Yuan X,
Dann AM, Ridinger-Saison M, DelGiorno KE, Antal CE, Liang G, et al:
Targeting LIF-mediated paracrine interaction for pancreatic cancer
therapy and monitoring. Nature. 569:131–135. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Ernst M and Putoczki TL: Molecular
pathways: IL11 as a tumor-promoting cytokine-translational
implications for cancers. Clin Cancer Res. 20:5579–5588. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Kang S, Narazaki M, Metwally H and
Kishimoto T: Historical overview of the interleukin-6 family
cytokine. J Exp Med. 217:e201903472020. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Zhao K, Lu Y, Chen Y, Cheng J and Zhang W:
Dual inhibition of MAPK and JAK2/STAT3 pathways is critical for the
treatment of BRAF mutant melanoma. Mol Ther Oncolytics. 18:100–108.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Huang B, Lang X and Li X: The role of
IL-6/JAK2/STAT3 signaling pathway in cancers. Front Oncol.
12:10231772022. View Article : Google Scholar :
|
|
139
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Updated analysis of KEYNOTE-024: Pembrolizumab versus
platinum-based chemotherapy for advanced non-small-cell lung cancer
with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol.
37:537–546. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Luo W, Wang Z, Zhang T, Yang L, Xian J, Li
Y and Li W: Immunotherapy in non-small cell lung cancer: Rationale,
recent advances and future perspectives. Precis Clin Med.
4:258–270. 2021. View Article : Google Scholar
|
|
141
|
Hayashi H, Sugawara S, Fukuda Y, Fujimoto
D, Miura S, Ota K, Ozawa Y, Hara S, Tanizaki J, Azuma K, et al: A
randomized phase II study comparing nivolumab with
carboplatin-pemetrexed for EGFR-mutated NSCLC with resistance to
EGFR tyrosine kinase inhibitors (WJOG8515L). Clin Cancer Res.
28:893–902. 2022. View Article : Google Scholar
|
|
142
|
Mok T, Nakagawa K, Park K, Ohe Y, Girard
N, Kim HR, Wu YL, Gainor J, Lee SH, Chiu CH, et al: Nivolumab plus
chemotherapy in epidermal growth factor receptor-mutated metastatic
non-small-cell lung cancer after disease progression on epidermal
growth factor receptor tyrosine kinase inhibitors: Final results of
CheckMate 722. J Clin Oncol. 42:1252–1264. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Yang JC, Lee DH, Lee JS, Fan Y, de Marinis
F, Iwama E, Inoue T, Rodríguez-Cid J, Zhang L, Yang CT, et al:
Phase III KEYNOTE-789 study of pemetrexed and platinum with or
without pembrolizumab for tyrosine kinase inhibitor-resistant,
EGFR-mutant, metastatic nonsquamous non-small cell lung cancer. J
Clin Oncol. 42:4029–4039. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Yu H, Kortylewski M and Pardoll D:
Crosstalk between cancer and immune cells: Role of STAT3 in the
tumour microenvironment. Nat Rev Immunol. 7:41–51. 2007. View Article : Google Scholar
|
|
145
|
Iwata-Kajihara T, Sumimoto H, Kawamura N,
Ueda R, Takahashi T, Mizuguchi H, Miyagishi M, Takeda K and
Kawakami Y: Enhanced cancer immunotherapy using STAT3-depleted
dendritic cells with high Th1-inducing ability and resistance to
cancer cell-derived inhibitory factors. J Immunol. 187:27–36. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Hossain DM, Dos Santos C, Zhang Q,
Kozlowska A, Liu H, Gao C, Moreira D, Swiderski P, Jozwiak A, Kline
J, et al: Leukemia cell-targeted STAT3 silencing and TLR9
triggering generate systemic antitumor immunity. Blood. 123:15–25.
2014. View Article : Google Scholar
|
|
147
|
Yu H, Pardoll D and Jove R: STATs in
cancer inflammation and immunity: A leading role for STAT3. Nat Rev
Cancer. 9:798–809. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Kortylewski M, Kujawski M, Wang T, Wei S,
Zhang S, Pilon-Thomas S, Niu G, Kay H, Mulé J, Kerr WG, et al:
Inhibiting Stat3 signaling in the hematopoietic system elicits
multicomponent antitumor immunity. Nat Med. 11:1314–1321. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Tan DSW, Felip E, de Castro G, Solomon BJ,
Greystoke A, Cho BC, Cobo M, Kim TM, Ganguly S, Carcereny E, et al:
Canakinumab versus placebo in combination with first-line
pembrolizumab plus chemotherapy for advanced non-small-cell lung
cancer: Results from the CANOPY-1 trial. J Clin Oncol. 42:192–204.
2024. View Article : Google Scholar
|
|
150
|
Zhang W, Liu Y, Yan Z, Yang H, Sun W, Yao
Y, Chen Y and Jiang R: IL-6 promotes PD-L1 expression in monocytes
and macrophages by decreasing protein tyrosine phosphatase receptor
type O expression in human hepatocellular carcinoma. J Immunother
Cancer. 8:e0002852020. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Zhou J, Lu X, Zhu H, Ding N, Zhang Y, Xu
X, Gao L, Zhou J, Song Y and Hu J: Resistance to immune checkpoint
inhibitors in advanced lung cancer: Clinical characteristics,
potential prognostic factors and next strategy. Front Immunol.
14:10890262023. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Tsukamoto H, Fujieda K, Miyashita A,
Fukushima S, Ikeda T, Kubo Y, Senju S, Ihn H, Nishimura Y and
Oshiumi H: Combined blockade of IL6 and PD-1/PD-L1 signaling
abrogates mutual regulation of their immunosuppressive effects in
the tumor microenvironment. Cancer Res. 78:5011–5022. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Mace TA, Shakya R, Pitarresi JR, Swanson
B, McQuinn CW, Loftus S, Nordquist E, Cruz-Monserrate Z, Yu L,
Young G, et al: IL-6 and PD-L1 antibody blockade combination
therapy reduces tumour progression in murine models of pancreatic
cancer. Gut. 67:320–332. 2018. View Article : Google Scholar
|
|
154
|
Jin W: Role of JAK/STAT3 signaling in the
regulation of metastasis, the transition of cancer stem cells, and
chemoresistance of cancer by epithelial-mesenchymal transition.
Cells. 9:2172020. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Danlos FX, Texier M, Job B, Mouraud S,
Cassard L, Baldini C, varga A, Yurchenko AA, Rabeau A, Champiat S,
et al: Genomic instability and protumoral inflammation are
associated with primary resistance to anti-PD-1 + antiangiogenesis
in malignant pleural mesothelioma. Cancer Discov. 13:858–879. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Yokota H, Sato K, Sakamoto S, Okuda Y,
Takeda M, Akamine Y, Nakayama K and Miura M: Influence of
interleukin-6 on the pharmacokinetics and pharmacodynamics of
osimertinib in patients with non-small cell lung cancer. Cancer
Chemother Pharmacol. 95:492025. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Martin FJ, Amode MR, Aneja A,
Austine-Orimoloye O, Azov AG, Barnes I, Becker A, Bennett R, Berry
A, Bhai J, et al: Ensembl 2023. Nucleic Acids Res. 51:D933–D941.
2023. View Article : Google Scholar :
|
|
158
|
Xie Y, Li H, Luo X, Li H, Gao Q, Zhang L,
Teng Y, Zhao Q, Zuo Z and Ren J: IBS 2.0: An upgraded illustrator
for the visualization of biological sequences. Nucleic Acids Res.
50(W1): W420–W426. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Fang Z, Ran H, Zhang Y, Chen C, Lin P,
Zhang X and Wu M: AlphaFold 3: An unprecedent opportunity for
fundamental research and drug development. Precis Clin Med.
8:pbaf0152025. View Article : Google Scholar : PubMed/NCBI
|
